SCHEMBL3466121

SCHEMBL3466121

COC(=O)C1CCCN1c1ccc(Cc2ccc(OC)c(-c3cccc(Cl)c3)c2F)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.39
ALDH1A1 P00352 3/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
GAA P10253 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PDCD1 Q15116 2/20 0.36
CD274 Q9NZQ7 2/20 0.36
MCHR1 Q99705 1/20 0.36
FPR2 P25090 1/20 0.36
SCN9A Q15858 1/20 0.36
ITGB1 P05556 1/20 0.36
ITGA4 P13612 1/20 0.36
ITGB7 P26010 1/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3466119 1.00 GRM5 (0.39) GRM5ALDH1A1HCRTR1HCRTR2GAA
SCHEMBL3466926 0.93 ITGB2 (0.40) GRM5HCRTR1HCRTR2PDCD1CD274
SCHEMBL3466742 0.93 ITGB2 (0.40) GRM5HCRTR1HCRTR2PDCD1CD274
SCHEMBL3466737 0.93 ITGB2 (0.40) GRM5HCRTR1HCRTR2PDCD1CD274
SCHEMBL3796904 0.92 FPR2 (0.40) GRM5HCRTR1HCRTR2CD274FPR2
SCHEMBL3796897 0.92 FPR2 (0.40) GRM5HCRTR1HCRTR2CD274FPR2
SCHEMBL3466246 0.88 GRM5 (0.37) GRM5HCRTR1HCRTR2PDCD1CD274
SCHEMBL3466221 0.88 GRM5 (0.37) GRM5HCRTR1HCRTR2PDCD1CD274
SCHEMBL13578424 0.88 GRM5 (0.37) GRM5HCRTR1HCRTR2CD274ITGA4
SCHEMBL13578423 0.88 GRM5 (0.37) GRM5HCRTR1HCRTR2CD274ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2628727-A2 Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders Decode Genetics EHF (IS) 2013-08-21 EP disclosed
US-20120213758-A1 BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS DeCODE Genetics enf (IS) 2012-08-23 US disclosed
EP-2222639-A1 BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS Decode Genetics EHF (IS) 2010-09-01 EP disclosed
US-20090136473-A1 BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS DECODE GENETICS EHF (IS) 2009-05-28 US disclosed
WO-2009067621-A1 BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS DECODE GENETICS EHF (IS) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136473-A1 BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS PDE4A, PDE4B, PDE3B GRM5 2332/4885ALDH1A1 149/4885HCRTR1 3931/4885
US-20120213758-A1 BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS PDE4A, PDE4B, PDE3B GRM5 2332/4885ALDH1A1 149/4885HCRTR1 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.